A novel podophyllotoxin-derived compound GL331 is more potent than its congener VP-16 in killing refractory cancer cells

Pharmaceutical Research

Volumn 16, Issue 7, 1999, Pages 997-1002

  Huang, Tze Sing ^a   Lee, Chun Chung ^a   Chao, Yee ^b   Shu, Chih Hung ^b   Chen, Li Tzong ^a   Chen, Li Li ^a   Chen, Min Hsiung ^b   Yuan, Chiou Chung ^b   Whang Peng, Jacqueline ^a  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Apoptosis; Cytotoxicity; GL33 I; VP 16

Indexed keywords

4' DEMETHYL 4BETA (4'' NITROANILINO) 4 DESOXYPODOPHYLLOTOXIN; CISPLATIN; DOXORUBICIN; ETOPOSIDE; ETOPOSIDE DERIVATIVE; FLUOROURACIL; GL 331; PODOPHYLLOTOXIN DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL SURVIVAL; COLON CARCINOMA; CONTROLLED STUDY; DNA DETERMINATION; DRUG CYTOTOXICITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LIVER CELL CARCINOMA; LYMPHOMA; MULTIDRUG RESISTANCE; NASOPHARYNX CARCINOMA; NEUROBLASTOMA; PRIORITY JOURNAL; STOMACH CARCINOMA; UTERINE CERVIX CARCINOMA;

EID: 0032784679     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018971313256     Document Type: Article

References (20)

1. J. Whang-Peng and T.-S. Huang. New trials of GL331, a novel topoisomerase II inhibitor, in treatment of solid tumors. J. Intern. Med. Taiwan 8:6-11 (1997).
2. T.-S. Huang, C.-H. Shu, Y.-L. Shih, H.-C. Huang, Y.-C. Su, Y. Chao, W. K. Yang, and J. Whang-Peng. Protein tyrosine phosphatase activities are involved in apoptotic cancer cell death induced by GL331, a new homolog of etoposide. Cancer Lett. 110:77-85 (1996).
3. M.-L. Kuo, S.-C. Shen, C.-H. Yang, S.-E. Chuang, A.-L. Cheng, and T.-S. Huang. Bcl-2 prevents topoisomerase II inhibitor GL331-induced apoptosis is mediated by down-regulation of poly(ADP-ribose)polymerase activity. Oncogene 17:2225-2234 (1998).
4. T.-S. Huang, W. K. Yang, and J. Whang-Peng. GL331-induced disruption of cyclin B1/CDC 2 complex and inhibition of CDC 2 kinase activity. Apoptosis 1:213-217 (1996).
5. T.-S. Huang, C.-H. Shu, W. K. Yang, and J. Whang-Peng. Activation of CDC 25 phosphatase and CDC 2 kinase involved in GL331-induced apoptosis. Cancer Res. 57:2974-2978 (1997).
6. R. B. Lock and W. E. Ross. DNA topoisomerases in cancer therapy. Anticancer Drug Design 2:151-164 (1987).
7. L. F. Liu. DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem. 58:351-375 (1989).
8. D. M. Sullivan, K.-C. Chow, and W. E. Ross. Topoisomerase II mediated mechanisms of drug resistance. In: D. Kessel (ed.), Resistance to antineoplastic drugs, pp. 281-292. FL: CRC Press, 1989.
9. C.-T. Lin, W.-Y. Chan, W. Chen, H.-M. Huang, H.-C. Wu, M.-M. Hsu, S.-M. Chuang, and C.-C. Wang. Characterization of seven newly established nasopharyngeal carcinoma cell lines. Lab. Invest. 68:716-27 (1993).
10. C.-W. Wu, Y.-F. Chang, T.-H. Yeh, T.-J. Chang, W.-Y. Lui, F.-K. P'Eng, and C.-W. Chi. Steroid hormone receptors in three human gastric cancer cell lines. Digest. Dis. Sci. 39:2689-94 (1994).
11. R.-Y. Shyu, S.-Y. Jiang, C.-C. Wang, M.-F. Wu, H.-J. Harn, T.- M. Chang, and M.-Y. Yeh. Establishment and characterization of TSGH9201, a human gastric carcinoma cell line that is growth inhibited by epidermal growth factor. J. Surg. Oncol. 58:17-24 (1995).
12. R. Overbeeke, H. Steffens-Nakken, I. Vermes, C. Reutelingsperger, and C. Haanen. Early features of apoptosis detected by four different flow cytometry assays. Apoptosis 3:115-121 (1998).
13. C.-H. Shu, W. K. Yang, and T.-S. Huang. Increased cyclin B1/ CDC 2 kinase activity and phosphorylation of Bcl-2 associated with paclitaxel-induced apoptosis in human nasopharyngeal carcinoma cells. Apoptosis 1:141-146 (1996).
14. Z.-Q. Wang, Y.-H. Kuo, D. Schnur, P. Bowen, S.-Y. Liu, F.-S. Han, J.-Y. Chang, Y.-C. Cheng, and K.-H. Lee. Antitumor agents. 113. New 4β-arylamino derivatives of 4′-O-demethylepipodophyllotoxic and related compounds as potent inhibitors of human DNA topoisomerase II. J. Med. Chem. 33:2660-2665 (1990).
15. J.-Y. Chang, F.-S. Han, S.-Y. Liu, Z.-Q. Wang, K.-H. Lee, and Y.-C. Cheng. Effect of 4β-arylamino derivatives of 4′-O-demethyepipodophyllotoxin on human DNA topoisomerase II, tubulin polymerization, KB cells, and their resistant variants. Cancer Res. 51:1755-1759 (1991).
16. S. E. Bates, S. J. Currier, M. Alvarez, and A. T. Fojo. Modulation of P-glycoprotein phosphorylation and drug transport by sodium butyrate. Biochemistry 31:6366-6372 (1992).
17. D. T. Aftab, J. M. Yang, and W. N. Hait. Functional role of phosphorylation of the multidrug transporter (P-glycoprotein) by protein kinase C in multidrug-resistant MCF-7 cells. Oncol. Res. 6:59-70 (1994).
18. W. P. Lee. P-glycoprotein is hyperphosphorylated in multidrug resistant HOB1 lymphoma cells treated with overdose of vineristine. Biochim. Biophys. Acta 1245:57-61 (1995).
19. S. Mishra and A.W. Hamburger. O-phospho-L-tyrosine inhibits cellular growth by activating protein tyrosine phosphatases. Cancer Res. 53:557-563 (1993).
20. A. Fandi, M. Altun, N. Azli, T. P. Armand, and E. Cvitkoric. Nasopharyngeal cancer, epidemiology, staging and treatment. Semin. Oncol. 21:382-388 (1994).